234 related articles for article (PubMed ID: 28867376)
1. A non-internalizing antibody-drug conjugate based on an anthracycline payload displays potent therapeutic activity in vivo.
Dal Corso A; Gébleux R; Murer P; Soltermann A; Neri D
J Control Release; 2017 Oct; 264():211-218. PubMed ID: 28867376
[TBL] [Abstract][Full Text] [Related]
2. Non-internalizing antibody-drug conjugates display potent anti-cancer activity upon proteolytic release of monomethyl auristatin E in the subendothelial extracellular matrix.
Gébleux R; Stringhini M; Casanova R; Soltermann A; Neri D
Int J Cancer; 2017 Apr; 140(7):1670-1679. PubMed ID: 27943268
[TBL] [Abstract][Full Text] [Related]
3. Protease-Cleavable Linkers Modulate the Anticancer Activity of Noninternalizing Antibody-Drug Conjugates.
Dal Corso A; Cazzamalli S; Gébleux R; Mattarella M; Neri D
Bioconjug Chem; 2017 Jul; 28(7):1826-1833. PubMed ID: 28662334
[TBL] [Abstract][Full Text] [Related]
4. Antibody-mediated delivery of interleukin-2 to the stroma of breast cancer strongly enhances the potency of chemotherapy.
Mårlind J; Kaspar M; Trachsel E; Sommavilla R; Hindle S; Bacci C; Giovannoni L; Neri D
Clin Cancer Res; 2008 Oct; 14(20):6515-24. PubMed ID: 18927291
[TBL] [Abstract][Full Text] [Related]
5. Efficient Payload Delivery by a Bispecific Antibody-Drug Conjugate Targeting HER2 and CD63.
de Goeij BE; Vink T; Ten Napel H; Breij EC; Satijn D; Wubbolts R; Miao D; Parren PW
Mol Cancer Ther; 2016 Nov; 15(11):2688-2697. PubMed ID: 27559142
[TBL] [Abstract][Full Text] [Related]
6. Engineered anti-CD70 antibody-drug conjugate with increased therapeutic index.
McDonagh CF; Kim KM; Turcott E; Brown LL; Westendorf L; Feist T; Sussman D; Stone I; Anderson M; Miyamoto J; Lyon R; Alley SC; Gerber HP; Carter PJ
Mol Cancer Ther; 2008 Sep; 7(9):2913-23. PubMed ID: 18790772
[TBL] [Abstract][Full Text] [Related]
7. Highly Potent, Anthracycline-based Antibody-Drug Conjugates Generated by Enzymatic, Site-specific Conjugation.
Stefan N; Gébleux R; Waldmeier L; Hell T; Escher M; Wolter FI; Grawunder U; Beerli RR
Mol Cancer Ther; 2017 May; 16(5):879-892. PubMed ID: 28258164
[TBL] [Abstract][Full Text] [Related]
8. Antibody Format and Drug Release Rate Determine the Therapeutic Activity of Noninternalizing Antibody-Drug Conjugates.
Gébleux R; Wulhfard S; Casi G; Neri D
Mol Cancer Ther; 2015 Nov; 14(11):2606-12. PubMed ID: 26294742
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of PNU-159682 antibody drug conjugates (ADCs).
Holte D; Lyssikatos JP; Valdiosera AM; Swinney Z; Sisodiya V; Sandoval J; Lee C; Aujay MA; Tchelepi RB; Hamdy OM; Gu C; Lin B; Sarvaiya H; Pysz MA; Laysang A; Williams S; Jun Lee D; Holda MK; Purcell JW; Gavrilyuk J
Bioorg Med Chem Lett; 2020 Dec; 30(24):127640. PubMed ID: 33127540
[TBL] [Abstract][Full Text] [Related]
10. A Novel Anti-CD22 Anthracycline-Based Antibody-Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs.
Yu SF; Zheng B; Go M; Lau J; Spencer S; Raab H; Soriano R; Jhunjhunwala S; Cohen R; Caruso M; Polakis P; Flygare J; Polson AG
Clin Cancer Res; 2015 Jul; 21(14):3298-306. PubMed ID: 25840969
[TBL] [Abstract][Full Text] [Related]
11. Tumor-targeting properties of novel antibodies specific to the large isoform of tenascin-C.
Brack SS; Silacci M; Birchler M; Neri D
Clin Cancer Res; 2006 May; 12(10):3200-8. PubMed ID: 16707621
[TBL] [Abstract][Full Text] [Related]
12. Targeting CD44 expressing cancer cells with anti-CD44 monoclonal antibody improves cellular uptake and antitumor efficacy of liposomal doxorubicin.
Arabi L; Badiee A; Mosaffa F; Jaafari MR
J Control Release; 2015 Dec; 220(Pt A):275-286. PubMed ID: 26518722
[TBL] [Abstract][Full Text] [Related]
13. Site-specifically traced drug release and biodistribution of a paclitaxel-antibody conjugate toward improvement of the linker structure.
Safavy A; Georg GI; Vander Velde D; Raisch KP; Safavy K; Carpenter M; Wang W; Bonner JA; Khazaeli MB; Buchsbaum DJ
Bioconjug Chem; 2004; 15(6):1264-74. PubMed ID: 15546192
[TBL] [Abstract][Full Text] [Related]
14. HER2-targeted antibody drug conjugates for ovarian cancer therapy.
Jiang J; Dong L; Wang L; Wang L; Zhang J; Chen F; Zhang X; Huang M; Li S; Ma W; Xu Q; Huang C; Fang J; Wang C
Eur J Pharm Sci; 2016 Oct; 93():274-86. PubMed ID: 27509865
[TBL] [Abstract][Full Text] [Related]
15. Modulating Therapeutic Activity and Toxicity of Pyrrolobenzodiazepine Antibody-Drug Conjugates with Self-Immolative Disulfide Linkers.
Pillow TH; Schutten M; Yu SF; Ohri R; Sadowsky J; Poon KA; Solis W; Zhong F; Del Rosario G; Go MAT; Lau J; Yee S; He J; Liu L; Ng C; Xu K; Leipold DD; Kamath AV; Zhang D; Masterson L; Gregson SJ; Howard PW; Fang F; Chen J; Gunzner-Toste J; Kozak KK; Spencer S; Polakis P; Polson AG; Flygare JA; Junutula JR
Mol Cancer Ther; 2017 May; 16(5):871-878. PubMed ID: 28223423
[TBL] [Abstract][Full Text] [Related]
16. Eradicating mesothelin-positive human gastric and pancreatic tumors in xenograft models with optimized anti-mesothelin antibody-drug conjugates from synthetic antibody libraries.
Hsu HJ; Tung CP; Yu CM; Chen CY; Chen HS; Huang YC; Tsai PH; Lin SI; Peng HP; Chiu YK; Tsou YL; Kuo WY; Jian JW; Hung FH; Hsieh CY; Hsiao M; Chuang SS; Shen CN; Wang YA; Yang AS
Sci Rep; 2021 Jul; 11(1):15430. PubMed ID: 34326410
[TBL] [Abstract][Full Text] [Related]
17. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity.
Ogitani Y; Hagihara K; Oitate M; Naito H; Agatsuma T
Cancer Sci; 2016 Jul; 107(7):1039-46. PubMed ID: 27166974
[TBL] [Abstract][Full Text] [Related]
18. Epratuzumab-SN-38: a new antibody-drug conjugate for the therapy of hematologic malignancies.
Sharkey RM; Govindan SV; Cardillo TM; Goldenberg DM
Mol Cancer Ther; 2012 Jan; 11(1):224-34. PubMed ID: 22039078
[TBL] [Abstract][Full Text] [Related]
19. Monoclonal Antibody Targeting Sialyl-di-Lewis
Tivadar ST; McIntosh RS; Chua JX; Moss R; Parsons T; Zaitoun AM; Madhusudan S; Durrant LG; Vankemmelbeke M
Mol Cancer Ther; 2020 Mar; 19(3):790-801. PubMed ID: 31871270
[TBL] [Abstract][Full Text] [Related]
20. IMGN853, a Folate Receptor-α (FRα)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors.
Ab O; Whiteman KR; Bartle LM; Sun X; Singh R; Tavares D; LaBelle A; Payne G; Lutz RJ; Pinkas J; Goldmacher VS; Chittenden T; Lambert JM
Mol Cancer Ther; 2015 Jul; 14(7):1605-13. PubMed ID: 25904506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
